Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px
Document › Details

Pieris Pharmaceuticals, Inc.. (3/25/15). "Press Release: Pieris Pharmaceuticals Reports Full-Year 2014 Financial Results and Provides Corporate Update". Freising.

Organisations Organisation Pieris Pharmaceuticals Inc. (Nasdaq: PIRS)
  Group Pieris (Group)
  Organisation 2 Sanofi (Group) [since May 2011]
Products Product PRS-080 (Anticalin hepcidin antagonist)
  Product 2 Anticalin® scaffold technology
  Index term 2 Pieris–SEVERAL: investment, 201412 private placement $13.56m with 6.8m shares common stock $2/share
Persons Person Yoder, Stephen S. (Steve) (Pieris 201001– CEO before MorphoSys Head Licensing + IP)
  Person 2 Richman, Michael (AstraZeneca 201411 CEO of Amplimmune Inc before Chiron + MedImmune + MacroGenics)
     


   
Record changed: 2017-04-02

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for Pieris (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px




» top